State-of-the-art diagnostic approaches, such as liquid biopsies coupled to Next Generation Sequencing, or high through-put mutational screening panels to assess circulating tumor cells or cell free tumor DNA (Hench et al., 2018; Vaughn et al., 2018), are increasing our abilities to recognize RET-targetable cancers or recurrent disease, without need for more invasive tumor biopsies (Reckamp et al., 2018). Here, RET is linked to neoplasm.